微信小陈
微信小章| 产品名称： | CHO DP-12 clone#1933 CHO DP-12, clone#1933 aIL8.92 NB 28605/12 |
|---|---|
| 商品货号： | TS190566 |
| Organism： | Cricetulus griseus, hamster, Chinese |
| Tissue： | ovary |
| Morphology： | fibroblast |
| Culture Properties： | adherent |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Images： |  |
| Derivation： | The clone#1933 aIL8.92 NB 28605/12 cell line was derived by co-transfecting the CHO cell line DP-12 using Lipofection with the vector p6G4V11N35A.choSD.9 designed to coexpress variable light and heavy regions of the murine 6G4.2.5 monoclonal antibody (ATCC HB-11722). Clones were selected in methotrexate. |
| Comments： | The cells are reported to produce 150 mg/L recombinant human anti-IL-8. Both the clone#1933 (TS190566) and clone#1934 (ATCC CRL-12445) antibodies inhibit IL-8 binding to human neutrophils. They also show equivalent neutralizing capabilities to inhibiting IL-8 mediated human neutrophil chemotaxis. The mammalian expression plasmid, p6G4V11N35AchoSD.9 (identified as p6G425V11N35A.choSD) is deposited as ATCC 209552. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: 200 nM methotrexate, 0.002 mg/ml recombinant human insulin, Trace Elements A (Cellgro) to a final concentration of 0.1%, Trace Elements B (Cellgro) to a final concentration of 0.1%, fetal bovine serum to a final concentration of 10%
|
| Subculturing： | Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:4 is recommended
Medium Renewal: Two to three times weekly
Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 10 in Culture of Animal Cells, a manual of Basic Technique by R. Ian Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994. |
| Cryopreservation： | Complete growth medium supplemented with 5% (v/v) DMSO. Cell culture tested DMSO is available as ATCC Catalog No. 4-X.
|
| Culture Conditions： | Temperature: 37°C
Atmosphere: Air, 95%; Carbon dioxide (CO2), 5% |
| Isotype： | human IgG1 |
| Name of Depositor： | Genetech, Inc. |
| U.S. Patent Number： | |
| Year of Origin： | 1933 |
| References： | Hsei V, et al. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,468,532 dated Oct 22 2002 Hsei V, et al. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,458,355 dated Oct 1 2002 Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,133,426 dated Oct 17 2000 Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,117,980 dated Sep 12 2000 Gonzalez TN, et al. Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies. US Patent 6,025,158 dated Feb 15 2000 Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. |